Coronavirus Vaccine / Amyris, Infectious Disease Research Institute - LARVOL DELTA

Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine. (PubMed, Nat Commun) - "Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19...These results demonstrate the ability of RBD-scNPs to induce broad neutralization of SARS-CoV-2 variants and to protect animals from multiple different SARS-related viruses. Such a vaccine could provide broad immunity to SARS-CoV-2 variants."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning with COVID-19 Vaccine (PRNewswire) - "Amyris, Inc...today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform....Amyris will co-own intellectual property developed to create the COVID-19 vaccine....Amyris has a strong research partnership with Universidade Católica Portuguesa. As part of this relationship we have advanced preliminary approval of a grant to fund the program through Phase 1 trials. We anticipate initiating a Phase 1 clinical trial around mid-2021....The vaccine development collaboration project for COVID-19 is expected to conclude in the first half of 2022."

Licensing / partnership • New P1 trial • Infectious Disease • Novel Coronavirus Disease